Singapore, Jan. 30 -- AstraZeneca has announced $15 billion investment in China through 2030 to expand medicines manufacturing and R&D. This investment will leverage the country's scientific excellence, advanced manufacturing, and China-UK healthcare ecosystem collaborations to deliver cutting-edge treatments to patients across China and globally.

Recognising China's advanced science in new modalities, this investment will significantly enhance the company's cell therapy and radioconjugates capabilities that are driving its broad and varied pipeline to help patients with cancer, haematological conditions and autoimmune diseases, among others.

These investments span the value chain, from drug discovery and clinical development to manufac...